Order Article Reprints

Prasenohadi P, Burhan E, Dhunny S, Suharno W, Wabnitz P, Kim Y-W, Petrosillo N. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. Journal of Clinical Medicine. 2022; 11(11):2961. https://doi.org/10.3390/jcm11112961

Prasenohadi, Prasenohadi, Erlina Burhan, Sri Dhunny, Wahyuningsih Suharno, Paul Wabnitz, Yoon-Won Kim, and Nicola Petrosillo. 2022. "Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19" Journal of Clinical Medicine 11, no. 11: 2961. https://doi.org/10.3390/jcm11112961

Prasenohadi, P., Burhan, E., Dhunny, S., Suharno, W., Wabnitz, P., Kim, Y.-W., & Petrosillo, N. (2022). Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. Journal of Clinical Medicine, 11(11), 2961. https://doi.org/10.3390/jcm11112961